Author

K. Iwatsuki-Horimoto

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 7 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Research Focus:host-pathogen & immune response· 7 Organism:mouse· 5 Organism:human· 3 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Assay:imaging· 1

Frequent Co-Authors

M. Imai· 8 shared Y. Kawaoka· 8 shared M. Ito· 7 shared M. Kiso· 5 shared S. Yamayoshi· 5 shared T. Maemura· 4 shared H. Ueki· 3 shared N. Ohmagari· 3 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

8 shared papersMicrobiology

M. Imai

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

Characterization of an EG.5.1 clinical isolate in vitro and in vivo

R. Uraki, M. Kiso, K. Iwatsuki-Horimoto, S. Yamayoshi, M. Ito, S. Chiba, Y. Sakai-Tagawa, M. Imai, Y. Kashima, M. Koga, N. Fuwa, N. Okumura, M. Hojo, N. Iwamoto, H. Kato, , Y. Kawaoka

This study characterizes the in vitro and in vivo properties of the EG.5.1 SARS-CoV-2 variant, showing increased transmissibility and altered antigenicity compared to XBB.1.5.

bioRxiv · Aug 31, 2023 · PreprintMicrobiology

Can SARS-CoV-2 transmit from a dead body?

K. Iwatsuki-Horimoto, H. Ueki, M. Ito, S. Nagasawa, Y. Hirata, K. Hashizume, K. Ushiwata, H. Iwase, Y. Makino, T. Ushiku, S. Akitomi, M. Imai, H. Saitoh, Y. Kawaoka

This study investigates SARS-CoV-2 transmission from dead bodies using a hamster model, finding that transmission is possible but can be prevented by postmortem care and embalming.

bioRxiv · Aug 29, 2022 · PreprintMicrobiology

Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates

R. Uraki, S. Iida, P. J. Halfmann, S. Yamayoshi, Y. Hirata, K. Iwatsuki-Horimoto, M. Kiso, M. Ito, Y. Furusawa, H. Ueki, Y. Sakai-Tagawa, M. Kuroda, T. Maemura, T. Kim, S. Mine, , Y. Kawaoka

This study evaluates the replicative ability and pathogenicity of SARS-CoV-2 BA.2.75 isolates in Syrian hamsters, finding higher lung replication and focal pneumonia compared to BA.2 and BA.5.

bioRxiv · Aug 26, 2022 · PreprintMicrobiology

Fc-modified SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models.

M. Takeshita, H. Fukuyama, K. Kamada, T. Matsumoto, C. Makino-Okamura, T. Uchikubo-Kamo, Y. Tomabechi, K. Hanada, S. Moriyama, Y. Takahashi, H. Ishigaki, M. Nakayama, C. T. Nguyen, Y. Kitagawa, Y. Itoh, , T. Takeuchi

The paper develops Fc-modified SARS-CoV-2 neutralizing antibodies effective against variants, showing reduced viral titers and lung damage in animal models.

bioRxiv · Jun 21, 2022 · PreprintMicrobiology

Highly-Neutralizing COVID-19-Convalescent-Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.

Y. Takamatsu, M. Imai, K. Maeda, N. Nakajima, N. Higashi-Kuwata, K. Iwatsuki-Horimoto, M. Ito, M. Kiso, T. Maemura, Y. Takeda, K. Omata, T. Suzuki, Y. Kawaoka, H. Mitsuya

This study shows that highly-neutralizing COVID-19 convalescent plasmas significantly reduce SARS-CoV-2 viral titers and lung lesions in Syrian hamsters compared to moderately neutralizing plasmas.

bioRxiv · Jun 29, 2021Microbiology

SARS-CoV-2 spike P681R mutation, a hallmark of the Delta variant, enhances viral fusogenicity and pathogenicity

A. Saito, T. Irie, R. Suzuki, T. Maemura, H. Nasser, K. Uriu, Y. Kosugi, K. Shirakawa, K. Sadamasu, I. Kimura, J. Ito, J. Wu, K. Iwatsuki-Horimoto, M. Ito, S. Yamayoshi, , K. Sato

This study shows the P681R mutation in the SARS-CoV-2 spike protein enhances fusogenicity and pathogenicity in the Delta variant compared to the prototypic virus.

bioRxiv · Jun 17, 2021Microbiology

Optimization of an LNP-mRNA vaccine candidate targeting SARS-CoV-2 receptor-binding domain

K. Kobiyama, M. Imai, N. Jounai, M. Nakayama, K. Hioki, K. Iwatsuki-Horimoto, S. Yamayoshi, J. Tsuchida, T. Niwa, T. Suzuki, M. Ito, S. Yamada, T. Watanabe, M. Kiso, H. Negishi, , K. J. Ishii

This study optimizes an LNP-mRNA vaccine targeting SARS-CoV-2 RBD by removing reactogenic materials, improving immunogenicity and protection in macaques.

bioRxiv · Mar 4, 2021 · PreprintImmunology

The anticoagulant nafamostat potently inhibits SARS-CoV-2 infection in vitro: an existing drug with multiple possible therapeutic effects

M. Yamamoto, M. Kiso, Y. Sakai-Tagawa, K. Iwatsuki-Horimoto, M. Imai, M. Takeda, N. Kinoshita, N. Ohmagari, J. Gohda, K. Semba, Z. Matsuda, Y. Kawaguchi, Y. Kawaoka, J.-i. Inoue

This study shows nafamostat inhibits SARS-CoV-2 infection in vitro by blocking TMPRSS2-mediated fusion, with potency exceeding its blood concentration, suggesting it as a potential COVID-19 treatment.

bioRxiv · Apr 22, 2020 · PreprintMicrobiology